The company
Freenome, Inc.
FRNM · Nasdaq
FRNM stood above a rising 150-day average in 25 of the last 52 weekly readings, and has been out of that trend for the last 1 week. It is 4.5% below that average now. Diagnostics & Labs: 48% of its 44 stocks in an uptrend (−2 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Setting up
- Weeks in an uptrend
- out for 1
- Industry in uptrend
- 48% -2 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $0
- Officials’ trades on record
- 0
- Institutions holding
- 0
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 25 of 52 weeks.
Diagnostics & Labs: About half its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
No open-market buy or sale by its insiders on record.
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|
News
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.